BioMarin Lifts FY Guidance Driven By Product Demand

California-based healthcare company, BioMarin Pharmaceutical Inc. (BMRN), provided an improved full-year outlook on Wednesday.

The company has narrowed its net loss outlook to a range of $85 million to $45 million, from prior estimate of $110 million to $60 million. On an adjusted basis, the outlook for net income is $215 million to $255 million, up from prior guidance of $190 million to $240 million.

Revenue outlook was improved to $1.82 billion to $1.88 billion, from prevoius forecast of $1.79 billion to $1.88 billion. On average, 17 analysts polled by Thomson Reuters are expecting revenue to come at $1.85 billion.

BioMarin expects Vimizim, Palynziq, and Kuvan to perform better than previously expected.

Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin said, "The essential nature of our medicines to the people who rely on them, gives us confidence in the growth prospects ahead. We plan to finish 2021 strong and expect meaningful growth in revenues in 2022 leading to anticipated GAAP profitability next year. We look forward to providing full guidance for 2022 early next year, especially given early demand signals for Voxzogo, for the treatment of achondroplasia, in Europe, and the potential for Voxzogo to be approved in the U.S. next month."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Rancho Cordova, California-based E-filliate Inc. is recalling about 301,800 units of DEWALT wireless earphones citing burn and fire risks, the U.S. Consumer Product Safety Commission said. The recall involves DEWALT Jobsite Pro Wireless Earphones, which have a black and yellow neckband with wired earbuds. According to the agency, the wireless earphones can overheat while charging or in use. The five-day holiday shopping period from Thanksgiving Day through Cyber Monday saw about 180 million Americans making in-store and online purchases, according to the National Retail Federation's Annual Thanksgiving Weekend Consumer Survey, conducted by Prosper Insights & Analytics. The shoppers spent an average of $301.27 on holiday-related purchases such as gifts, décor, apparel and toys. Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern,...
Follow RTT